Senior insider sale
EVP of R&D at ALLOGENE THERAPEUTICS, INC. — senior position signals high conviction
$104.3K
61.97K shares
What this filing means
ROBERTS ZACHARY plans to sell 61.97K shares of ALLOGENE THERAPEUTICS, INC. valued at approximately $104.3K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 2/2/2026ACC: 0001950047-26-000849
Officer· EVP of R&D
Since Feb 2026
61.97K
Shares to sell
$104.3K
Approx. market value
35.70K
Acquired (3 months)
1
Planned
1 completed
Securities Acquired — Last 3 Months1
Restricted stock vesting under a registered plan
Compensation
1/31/2026
35.70KTotal acquired35.70K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
1/31/2026 | Restricted stock vesting under a registered plan Compensation | 35.70K | — |
| Total | 35.70K | ||
Planned & Completed Dispositions2
Completed
—Completed
Units to sell
26.27K
Market value
$41.0K
1/21/2026
Planned — Approximate Date
NASDAQPlanned
Units to sell
35.70K
Market value
$63.4K
2/2/2026
Total
Units
61.97K
Value
$104.3K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
1/21/2026 | 26.27K | $41.0K | — | Completed |
| Planned — Approximate Date | ||||
2/2/2026 | 35.70K | $63.4K | NASDAQ | Planned |
| Total | 61.97K | $104.3K | ||